Evidence map›Paper›PMID 31492893›Full record

ArticleScientific reports2019

Clinical Model for Predicting Warfarin Sensitivity.

Zhiyuan Ma, Gang Cheng, Ping Wang, Bahar Khalighi, Koroush Khalighi

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Personalized medicine in cardiovascular disease: review of literature.Journal of diabetes and metabolic disorders · 2021
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Zhiyuan MaEaston Cardiovascular Associates, Easton, PA, USA.
Gang ChengDepartment of Medicine, Easton Hospital, Easton, PA, USA.ORCID http://orcid.org/0000-0002-8312-4599
Ping WangDivision of Surgical Sciences, Department of Surgery, Duke University Medical Center, Durham, NC, USA.
Bahar KhalighiSchool of Pharmacy, Temple University, Philadelphia, PA, USA.
Koroush KhalighiEaston Cardiovascular Associates, Easton, PA, USA. koroushkhalighi@gmail.com.
Duke Medical Center · USEaston Hospital · USLehigh Valley Hospital-Pocono · USTemple University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Warfarin is a widely used anticoagulant with a narrow therapeutic index and large interpatient variability in the therapeutic dose. Complications from inappropriate warfarin dosing are one of the most common reasons for emergency room visits. Approximately one third of warfarin dose variability results from common genetic variants. Therefore, it is very necessary to recognize warfarin sensitivity in individuals caused by genetic variants. Based on combined polymorphisms in CYP2C9 and VKORC1, we established a clinical classification for warfarin sensitivity. In the International Warfarin Pharmacogenetic Consortium (IWPC) with 5542 patients, we found that 95.1% of the Black in the IWPC cohort were normal warfarin responders, while 74.8% of the Asian were warfarin sensitive (P < 0.001). Moreover, we created a clinical algorithm to predict warfarin sensitivity in individual patients using logistic regression. Compared to a fixed-dose approach, the clinical algorithm provided significantly better performance. In addition, we validated the derived clinical algorithm using the external Easton cohort with 106 chronic warfarin users. The AUC was 0.836 vs. 0.867 for the Easton cohort and the IWPC cohort, respectively. With the use of this algorithm, it is very likely to facilitate patient care regarding warfarin therapy, thereby improving clinical outcomes.

Indexed as

Polymorphism, Single NucleotideAgedAged, 80 and overAlgorithmsAnticoagulantsCohort StudiesCytochrome P-450 CYP2C9Drug ResistanceFemaleGenotypeHumansLogistic ModelsMaleMetabolism, Inborn ErrorsMiddle AgedPharmacogenomic VariantsAnticoagulantsCytochrome P-450 CYP2C9Vitamin K Epoxide ReductasesVKORC1 protein, humanWarfarin

Identifiers

PMID31492893
PMCPMC6731233
OpenAlexW2971757228

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.